Green Cross Cell Corp (031390) - Financial and Strategic SWOT Analysis Review

Green Cross Cell Corp (031390) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Green Cross Cell Corp (GC Cell), a subsidiary of Green Cross Corp, is a provider of immunotherapeutics for the treatment of cancer. The company offers Immuncell-LC, an anti-cancer immune therapeutic that is derived from lymphocytes of cancer patient. It offers cryopreservation of cord blood that contains stem cells, which can be used to treat various diseases such as pediatric cancer, leukemia, stroke, diabetes, and liver diseases, among others. GC Cell offers contract services ranging from manufacturing of the biopharmaceuticals, cell storage, processing, and consulting, to the product delivery. The company also carries out research programs targeted at the treatment of leukemia, pancreatic cancer, ovarian cancer, acquired immunodeficiency syndrome (AIDS) and glioblastoma. GC Cell is headquartered in Seoul, South Korea.

Green Cross Cell Corp Key Recent Developments

Jul 20, 2021: GC Green Cross and Aprogen signed an MOU for consignment production business cooperation
May 24, 2021: GC Green Cross Healthcare acquires ISMS-P certification for the first time in the Industry
Apr 28, 2021: UB Care records 26.4 billion won in sales in the first quarter
Apr 28, 2021: GC Green Cross Lab Cell, sales of 27.3 billion won in the first quarter
Apr 15, 2021: GC Green Cross Well-Being applied for an international patent for placental-derived antiviral composition

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Section 1 - About the Company

Green Cross Cell Corp - Key Facts
Green Cross Cell Corp - Key Employees
Green Cross Cell Corp - Key Employee Biographies
Green Cross Cell Corp - Major Products and Services
Green Cross Cell Corp - History
Green Cross Cell Corp - Company Statement
Green Cross Cell Corp - Locations And Subsidiaries
Head Office

Section 2 - Company Analysis

Company Overview
Green Cross Cell Corp - Business Description
R&D Overview
Green Cross Cell Corp - Corporate Strategy
Green Cross Cell Corp - SWOT Analysis
SWOT Analysis - Overview
Green Cross Cell Corp - Strengths
Green Cross Cell Corp - Weaknesses
Green Cross Cell Corp - Opportunities
Green Cross Cell Corp - Threats
Green Cross Cell Corp - Key Competitors

Section 3 - Company Financial Ratios

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances

Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Green Cross Cell Corp, Recent Deals Summary

Section 5 - Company’s Recent Developments

Jul 20, 2021: GC Green Cross and Aprogen signed an MOU for consignment production business cooperation
May 24, 2021: GC Green Cross Healthcare acquires ISMS-P certification for the first time in the Industry
Apr 28, 2021: UB Care records 26.4 billion won in sales in the first quarter
Apr 28, 2021: GC Green Cross Lab Cell, sales of 27.3 billion won in the first quarter
Apr 15, 2021: GC Green Cross Well-Being applied for an international patent for placental-derived antiviral composition
Apr 13, 2021: GCL expands its clinical trial sample analysis laboratory
Apr 07, 2021: GC Well-Being, applied for an international patent for a composition for preventing and treating liver disease
Mar 22, 2021: GC Green Cross Lab Cell acquires domestic patent for NK cell manufacturing method
Mar 11, 2021: GCL acquires International Standard 'ISO 15189 Accreditation'
Feb 02, 2021: GC Green Cross Lab Cell acquires Australian patent for CAR signaling domain

Section 6 - Appendix

Methodology
Ratio Definitions
About the Publisher

List of Tables

Green Cross Cell Corp, Key Facts
Green Cross Cell Corp, Key Employees
Green Cross Cell Corp, Key Employee Biographies
Green Cross Cell Corp, Major Products and Services
Green Cross Cell Corp, History
Green Cross Cell Corp, Key Competitors
Green Cross Cell Corp, Ratios based on current share price
Green Cross Cell Corp, Annual Ratios
Green Cross Cell Corp, Interim Ratios
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Green Cross Cell Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Green Cross Cell Corp, Performance Chart (2016 - 2020)
Green Cross Cell Corp, Ratio Charts
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021